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Bmi-1 is a polycomb protein that plays an important role in tumor cell development and maintain-
ing stem cell populations of many cell lineages. Here we identify a polymorphism in human Bmi-1
that changes a cysteine within its RING domain to tyrosine. This C18Y polymorphism is associated
with a signiﬁcant decrease in Bmi-1 level and its elevated ubiquitination, suggesting that it is being
destroyed by the ubiquitin–proteasome system. Consistent with this, treating cells with the protea-
some inhibitor MG-132 signiﬁcantly increases C18Y Bmi-1 levels. This is the ﬁrst example of a poly-
morphism in Bmi-1 that reduces levels of this important protein.
Structured summary:
MINT-6948574: Bmi-1 (uniprotkb:P35226) physically interacts (MI:0218) with Ubiquitin (uni-
protkb:P62988) by anti tag coimmunoprecipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bmi-1 is a member of the polycomb group family of proteins,
which function as negative regulators of the transcription of a
number of important target genes [1–6]. Bmi-1 was ﬁrst cloned
as a c-myc cooperating oncogene in murine lymphomas [7,8],
and found to have signiﬁcant sequence relatedness to Drosophila
polycomb proteins [9,10]. Previous studies have identiﬁed several
ways in which Bmi-1 mediates its effects on cell proliferation,
including inhibiting expression of the Ink4A/ARF locus [11,12],
modulating the p21-Rb pathway [13], and inducing telomerase
activity [14].
In addition to its function as an oncogene, Bmi-1 also plays
important roles in determination of cell fate and stem cell renewal
of the neural, hematopoietic, and other cell lineages [15–23]. Bmi-
1 contains a conserved RING-ﬁnger domain near the NH2 terminus,
which is important for the function of this protein [7,14,24–27].
Bmi-1 has been found to be predominantly localized to the nu-
cleus, which is mediated by a nuclear localization sequence (NLS)
located in the C-terminal region of this protein [14,24,28].
In this paper we characterize a polymorphism in the human
Bmi-1 protein that changes a cysteine in the RING-ﬁnger domainchemical Societies. Published by E
Molecular and Cellular Bio-
ntucky, Lexington, KY 40536,(cysteine 18) to tyrosine. The results show that the C18Y polymor-
phism results in a signiﬁcant reduction in levels of the Bmi-1 pro-
tein by leading to its ubiquitination and destruction by the
proteasome. In light of the important functions of Bmi-1 in stem
cell renewal and determination of cellular identity, these results
suggest that this C18Y polymorphism could have deleterious ef-
fects in the people that have it.2. Materials and methods
2.1. SNP database searching
To identify potential polymorphisms within the Bmi-1 gene, we
searched the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/
index.html). This search identiﬁed a SNP polymorphism
(rs1042059) that is predicted to change the cysteine at amino acid
18 of Bmi-1 to tyrosine. This Bmi-1 C18Y polymorphism was found
in both the CEU (ancestry from northern and western Europe) and
YRI (Yoruba in Ibadan, Nigeria) populations that were analyzed by
the International HapMap Project [29–31].
2.2. Cell culture and plasmids
HEK 293T cells were grown at 37 C in DMEM supplemented
with 10% FBS and 100 antibiotic–antimycotic (Invitrogen) in 5%
CO2. pEGFP-Bmi-1 plasmid was generated by using PCR to amplifylsevier B.V. All rights reserved.
Fig. 1. Identiﬁcation of a SNP resulting in a C18Y polymorphism of Bmi-1. (A)
Schematic showing the location of the RING-ﬁnger and NLS in the Bmi-1 protein, as
well as its nuclear localization sequence (NLS). (B) Schematic showing the amino
acid sequence of the RING-ﬁnger domain and location of the C18Y polymorphism of
Bmi-1.
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BC011652, Open Biosystems) a coding fragment of Bmi-1 having
KpnI and BamHI sites at the ends using the following primers:
50-GCG GGT ACC ATG CAT CGA ACA ACG AGA-30 and 50-CGC GGA
TCC TCA ACC AGA AGA AGT TGC TGA-30. This PCR product was then
cloned into pEGFP-C1 vector at the KpnI and BamHI sites to make
the pEGFP-Bmi-1 plasmid. This plasmid was conﬁrmed by DNA
sequencing. pEGFP-C18Y-Bmi-1 plasmid was generated using the
QuickChange mutagenesis method (Stratagene) according to the
manufacturer’s protocol. The mutation was conﬁrmed by DNA
sequencing.
2.3. Fluorescence microscopy
HEK293 cells were seeded onto coverslips that were
acid-washed and ﬂamed, and then coated with laminin (5 lg/ml)
(Sigma–Aldrich). Forty-eight hours after transfection with the
plasmids encoding the wild-type or C18Y GFP-Bmi-1 fusion
proteins, cells were washed twice in ice-cold 1 PBS, followed by
ﬁxation in 3.7% paraformaldehyde for 20 min at room temperature.
After a ﬁnal wash with PBS, coverslips were mounted on a slide
with Vectashield mounting medium plus 1.5 lg/ml DAPI (40,6
diamidino-2-phenylindole) (Vector Laboratories). Fluorescence of
the GFP-Bmi-1 proteins was visualized using a Nikon ﬂuorescent
microscope with a 100 oil immersion objective and a Nikon
Spotcam digital-imaging camera.
2.4. Extract preparation and Western blot assay
HEK293 cells were transfected with the wild-type or C18Y GFP-
Bmi-1 expression plasmids using Jet-PEI reagent according to the
manufacturer’s instructions. At 48 h post-transfection, cells were
extracted on ice with NP-40 lysis buffer (1% NP-40, 50 mM Tris–
HCl (pH 8.0), 150 mM NaCl, 1 mM dithiothreitol, complete prote-
ase inhibitor cocktail (Roche Applied Science) and 20 mM N-ethyl-
maleimide (added fresh)) for 20 min. After centrifugation at
13000 rpm at 4 C for 10 min, the supernatant was transferred to
a fresh tube, and then the whole cell lysate was used for the follow-
ing assays. SDS–PAGE and Western blot were performed according
to standard protocols. Goat anti-GFP antibody (Bethyl Laboratories
Inc.) was used for theWestern blots at 1:2000. For the immunopre-
cipitation assay of ubiquitinated Bmi-1, mouse monoclonal anti-
ubiquitin antibody (gift of Dr. Haining Zhu, University of Kentucky,
Lexington, KY) was used at 1:1000.
2.5. Proteasome inhibition assay
HEK293T cells were transfected with the wild-type or C18Y
GFP-Bmi-1 expression plasmids as described above, except that
at 44 h post-transfection 10 lM MG-132 proteasome inhibitor
(Calbiochem, gift of Dr. Dan Noonan, University of Kentucky,
Lexington, KY) was added to the media and the cells incubated
for 4 more hours.
2.6. Bmi-1 ubiquitination assay
HEK293T cells were transfected with pEGFP-Bmi-1 or pEGFP-
C18Y-Bmi-1 as described above. At 48 h post-transfection, cells
were extracted on ice with NP-40 lysis buffer (1% NP-40, 50 mM
Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM dithiothreitol, complete
protease inhibitor cocktail (Roche Applied Science) and 20 mM
N-ethylmaleimide (added fresh)) for 20 min. Lysates were then
cleared by centrifugation at 13 000 rpm for 10 min at 4 C. Super-
natants were precleared by incubation with goat (control) IgG
and protein G-sepharose beads for 2 h at 4 C with gentle rotation.
Precleared extracts were then incubated with primary goat poly-clonal anti-GFP antibody or control IgG and 50% slurry of protein
G-sepharose for 4 h at 4 C with rotation. After washing beads 6
times for 5 min each at 4 C with NP-40 buffer, bound proteins
were released by boiling in SDS–PAGE sample dye and analyzed
by Western blot assay using the anti-ubiquitin mouse monoclonal
antibody or anti-GFP goat polyclonal antibody.3. Results
As depicted in Fig. 1A, the Bmi-1 protein contains a RING-ﬁnger
domain in its N-terminal region [7,14,24–27]. Examination of the
dbSNP database revealed the existence of a polymorphism in
human Bmi-1 that changes amino acid 18, a cysteine in the
RING-ﬁnger domain, to tyrosine (Fig. 1B). Further analysis revealed
that individuals that are heterozygous for this polymorphism are
found in both the CEU (Utah residents with ancestry from northern
and western Europe) and YRI (Yoruba in Ibadan, Nigeria)
populations that were studied as part of the International HapMap
Project [29–31].
Because the cysteine that is changed to tyrosine in this poly-
morphism is a residue of the RING-ﬁnger domain, we hypothesized
that this alteration could lead to alteration in the functional
properties of the Bmi-1 protein. Bmi-1 has been found to be a
predominantly nuclear-localized protein [14,24,28], mediated by
a nuclear localization sequence (NLS) in the C-terminal region
(Fig. 1A) [14,24]. Therefore, one functional property of Bmi-1 we
hypothesized could be affected by the C18Y polymorphism is its
pattern of localization within the cell. To test this hypothesis we
transfected wild-type and C18Y GFP-Bmi-1 expression plasmids
into HEK293 cells and then examined the sub-cellular localization
of the transfected proteins using ﬂuorescence microscopy analysis.
The results of this experiment, shown in Fig. 2, revealed that the
wild-type and C18Y Bmi-1 proteins both exhibit predominant
nuclear localization, indicating that the C18Y polymorphism does
not appear to signiﬁcantly alter the sub-cellular localization of
the Bmi-1 protein.
Although the results of the ﬂuorescence microscopy experiment
shown in Fig. 2 did not indicate a difference in localization, they
did show that the intensity of the signal from the C18Y GFP-Bmi-
1 was markedly less than that exhibited by wild-type Bmi-1. This
suggested that the C18Y polymorphism may be associated with a
decrease in levels of the Bmi-1 protein. To test this we subjected
extracts of HEK293 cells transfected with the wild-type or C18Y
GFP-Bmi-1 expression plasmids to Western blot assay with anti-
GFP antibodies to detect the transfected Bmi-1 proteins, or with
b-actin antibodies as a loading control. The results of this experi-
ment show that the levels of the C18Y GFP-Bmi-1 protein are
Fig. 2. Fluorescence microscopy analysis of wild-type and C18Y Bmi-1 localization in cells. (A) Wild-type and C18Y GFP-Bmi-1 expression plasmids were transfected into HEK
293T cells, and the sub-cellular localization of the GFP-Bmi-1 proteins examined by ﬂuorescence microscopy. GFP images shown are 1.25 s exposures. DNA was visualized by
staining with DAPI. (B) Fluorescence microscopy analysis of wild-type GFP-Bmi-1 taken at shorter exposure time for the GFP channel (0.45 s) than that shown in panel A.
Fig. 3. C18Y polymorphism is associated with a signiﬁcant decrease in Bmi-1
protein level. Wild-type or C18Y GFP-Bmi-1 expression plasmids were transfected
into HEK293 cells, and then extracts prepared from the transfected cells were
subjected to Western blot assay using anti-GFP antibodies (upper panel), or anti-b-
actin antibodies as a loading control (lower panel).
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(Fig. 3).
We hypothesized that the C18Y polymorphism could be result-
ing in decreased levels of Bmi-1 by leading to increased destruction
of this protein by the ubiquitin–proteasome degradation pathway.
To test this hypothesis, we subjected extracts of HEK293 cells
transfected with the wild-type or C18Y GFP-Bmi-1 expression plas-
mids to immunoprecipitation using anti-GFP antibodies or non-
speciﬁc IgG control antibodies, followed by Western blot assay
with anti-ubiquitin antibodies to compare the amounts of ubiqui-
tinated forms of the transfected wild-type vs. C18Y Bmi-1 proteins.
The results of this analysis, shown in Fig. 4A, indicate that C18Y
Bmi-1 exhibits signiﬁcantly higher levels of ubiquitination than
wild-type Bmi-1. Next, to test the involvement of the proteasome
in the lower protein levels of C18Y Bmi-1, we tested whether levels
of this form of Bmi-1 increase in cells that have been treated with
the proteasome inhibitor MG-132. The results of this experiment
show that MG-132 treatment does indeed result in the presence
of signiﬁcantly higher levels of the C18Y Bmi-1 protein (Fig. 4B).
The results shown in Fig. 4 support the hypothesis that the C18Y
polymorphism of Bmi-1 leads to lower levels of this protein by
Fig. 4. C18Y Bmi-1 protein is degraded by the ubiquitin–proteasome system. (A)
HEK293 cells were transfected with wild-type or C18Y GFP-Bmi-1 expression
plasmids, and then extracts of the cells were subjected to immunoprecipitation
with anti-GFP antibodies (goat polyclonal) or non-speciﬁc IgG (negative control),
followed by anti-ubiquitin Western blot to detect the ubiquitinated forms of Bmi-1.
(B) Wild-type or C18Y GFP-Bmi-1 expression plasmids were transfected into
HEK293 cells, in the absence or presence of 10 lM MG-132 proteasome inhibitor
(inhibitor added at 44 h post-transfection and incubated for 4 h). Extracts prepared
from the transfected cells were then subjected to Western blot assay using anti-GFP
antibodies (upper panel), or anti-b-actin antibodies as a loading control (lower
panel).
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pathway.
4. Discussion
The results described in this paper characterize a polymorphism
in the human Bmi-1 protein that changes the cysteine at amino
acid position 18 to tyrosine (C18Y). The results also show that
the levels of C18Y Bmi-1 are signiﬁcantly lower than that of the
wild-type protein, and that this lower level of C18Y Bmi-1 is asso-
ciated with its increased ubiquitination and degradation by the
proteasome. This is the ﬁrst demonstration of a polymorphism in
human Bmi-1 that leads to alteration in levels of this important
protein. Cysteine 18 is part of the RING-ﬁnger motif responsible
for binding zinc. Thus, we hypothesize that the most likely expla-
nation for the decreased level of C18Y Bmi-1 is that changing this
cysteine to tyrosine disrupts the structure of the RING domain,
leading to its recognition as a mal-folded protein by the ubiquitina-
tion machinery, covalent ubiquitin attachment, and subsequent
degradation by the proteasome.
In a previous study the effect of deleting the entire RING-
ﬁnger on the turnover of Bmi-1 was examined [32]. The results
of pulse-chase experiments suggested that deletion of the RING-
ﬁnger did not signiﬁcantly change the half-life of the Bmi-1
protein. However, steady-state levels of the RING-ﬁnger-deleted
Bmi-1 were signiﬁcantly lower than that of the wild-typeBmi-1, and MG-132 treatment resulted in a signiﬁcantly larger
increase in levels of the RING-ﬁnger mutant compared to the
wild-type Bmi-1. Thus, we think one interpretation of these ﬁnd-
ings is that deleting the RING-ﬁnger of Bmi-1 may have at least
some effect on the stability of this protein. In any event, we think
it is difﬁcult to compare these results with ours because in the
previous study the entire RING domain of Bmi-1 was deleted,
whereas our study examines the effect of a single amino acid
change in the RING-ﬁnger domain.
Bmi-1 is important for the determination of cell fate and the re-
newal of adult stem cells of a number of cell lineages, including
neural, hematopoietic, and intestinal lineages [15–23]. Since the
C18Y Bmi-1 polymorphism is associated with a signiﬁcant de-
crease in Bmi-1 levels, one hypothesis that we think should be
tested in future studies is whether people with the C18Y form of
Bmi-1 may be affected by problems such as decreased ability to re-
new stem cells. In support of this hypothesis, mouse studies have
shown that even Bmi-1+/ heterozygote mice exhibit phenotypic
differences in stem cell characteristics compared to wild-type
mice, although they are not as severe as those observed for
Bmi-1/ mice [16–18,33]. We acknowledge that our conclusions
are based on studies of exogenously expressed C18Y vs. wild-type
Bmi-1 proteins, but our results indicating that both the ubiquitina-
tion and proteasomal degradation pathways are functioning in
these cells suggest that the results are likely not due to any major
perturbations of either of these processes by expression of the Bmi
proteins. In addition to its importance for stem cell renewal and
cell identity, Bmi-1 also has oncogenic functions [7,8,11–14]. Thus,
it is conceivable that the decreased levels of Bmi-1 expected in
people with the C18Y polymorphism could be beneﬁcial to these
people in terms of decreasing their risk of cancer. In support of this,
mice lacking Bmi-1 showed a decreased incidence of tumor cells
[34,35]. Intriguingly, even cells from Bmi-1+/ heterozygous mice
showed a signiﬁcant decrease in tumor formation [12], suggesting
that individuals with the C18Y Bmi-1 polymorphism may have a
lower susceptibility to developing tumors. This hypothesis could
be tested in future studies.
In summary, the results of our study suggest that the C18Y
polymorphism of Bmi-1 leads to decreased levels of Bmi-1, and
that this is due to degradation of this variant protein by the ubiq-
uitin–proteasome system. We think these results warrant future
studies to test the effect of the C18Y Bmi-1 polymorphism in the
context of the whole animal. The results of such studies could pro-
vide new insight into the importance of Bmi-1 for stem cell renew-
al and other processes in which it is thought to be involved.
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